{"entity":{"type":"insider","cik":"0001304395","url":"/insider/0001304395","json_url":"/insider/0001304395.json","name":"Bitterman Robert J","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":29,"n_filings":21,"first":"2013-08-05","last":"2026-08-19","span_basis":"filed_date"},"name_variants":[{"name":"Bitterman Robert J","source":"filing","n_filings":21,"first_seen":"2013-08-05","last_seen":"2026-08-19"}],"transactions":[{"id":9298406,"accession":"0001683168-26-006592","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001683168-26-006592","line_url":"/filing/0001683168-26-006592#line-1","is_derivative":false,"issuer_cik":"0001533040","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001533040","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Chairman, Pres. & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, Pres. & CEO","security_title":"Common Stock, $.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":1.06,"price_display":"1.06","price_state":"stated","total_value":10600.0,"total_display":"10,600.00","total_whole":"10,600","shares_owned_after":431421.0,"shares_owned_after_display":"431,421","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-18","filed_date":"2026-08-19","scope":"insider"},{"id":5815381,"accession":"0001683168-26-005164","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001683168-26-005164","line_url":"/filing/0001683168-26-005164#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Chairman, Pres. & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, Pres. & CEO","security_title":"Common Stock, $.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":0.99,"price_display":"0.99","price_state":"stated","total_value":9900.0,"total_display":"9,900.00","total_whole":"9,900","shares_owned_after":421421.0,"shares_owned_after_display":"421,421","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-26","filed_date":"2026-06-29","scope":"insider"},{"id":5788206,"accession":"0001683168-26-000013","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001683168-26-000013","line_url":"/filing/0001683168-26-000013#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Chairman, Pres. & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, Pres. & CEO","security_title":"Common Stock, $.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":1.03,"price_display":"1.03","price_state":"stated","total_value":5150.0,"total_display":"5,150.00","total_whole":"5,150","shares_owned_after":291421.0,"shares_owned_after_display":"291,421","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-31","filed_date":"2026-01-02","scope":"insider"},{"id":4207551,"accession":"0001683168-25-009349","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001683168-25-009349","line_url":"/filing/0001683168-25-009349#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Chairman, Pres. & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, Pres. & CEO","security_title":"Common Stock, $.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":1.02,"price_display":"1.02","price_state":"stated","total_value":5100.0,"total_display":"5,100.00","total_whole":"5,100","shares_owned_after":286421.0,"shares_owned_after_display":"286,421","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-23","filed_date":"2025-12-29","scope":"insider"},{"id":5098066,"accession":"0001683168-25-008639","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001683168-25-008639","line_url":"/filing/0001683168-25-008639#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Chairman, Pres. & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, Pres. & CEO","security_title":"Common Stock, $.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":1.14,"price_display":"1.14","price_state":"stated","total_value":5700.0,"total_display":"5,700.00","total_whole":"5,700","shares_owned_after":281421.0,"shares_owned_after_display":"281,421","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-21","filed_date":"2025-11-24","scope":"insider"},{"id":4812744,"accession":"0001683168-25-008537","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001683168-25-008537","line_url":"/filing/0001683168-25-008537#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Chairman, Pres. & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, Pres. & CEO","security_title":"Common Stock, $.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":1.27,"price_display":"1.27","price_state":"stated","total_value":6350.0,"total_display":"6,350.00","total_whole":"6,350","shares_owned_after":276421.0,"shares_owned_after_display":"276,421","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-18","filed_date":"2025-11-19","scope":"insider"},{"id":4167414,"accession":"0001062993-25-011424","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-25-011424","line_url":"/filing/0001062993-25-011424#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Chairman, Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, Pres & CEO","security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":2.42,"price_display":"2.42","price_state":"stated","total_value":4840.0,"total_display":"4,840.00","total_whole":"4,840","shares_owned_after":27149.0,"shares_owned_after_display":"27,149","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-10","filed_date":"2025-06-11","scope":"insider"},{"id":4390797,"accession":"0001062993-25-011326","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-25-011326","line_url":"/filing/0001062993-25-011326#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Chairman, Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, Pres & CEO","security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1500.0,"shares_display":"1,500","price_per_share":2.75,"price_display":"2.75","price_state":"stated","total_value":4125.0,"total_display":"4,125.00","total_whole":"4,125","shares_owned_after":25149.0,"shares_owned_after_display":"25,149","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-09","filed_date":"2025-06-10","scope":"insider"},{"id":4167355,"accession":"0001062993-25-010155","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-25-010155","line_url":"/filing/0001062993-25-010155#line-2","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Chairman, Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, Pres & CEO","security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1200.0,"shares_display":"1,200","price_per_share":1.7799,"price_display":"1.78","price_state":"stated","total_value":2135.88,"total_display":"2,135.88","total_whole":"2,136","shares_owned_after":23649.0,"shares_owned_after_display":"23,649","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-22","filed_date":"2025-05-23","scope":"insider"},{"id":4167352,"accession":"0001062993-25-010155","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-25-010155","line_url":"/filing/0001062993-25-010155#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Chairman, Pres & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chairman, Pres & CEO","security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3000.0,"shares_display":"3,000","price_per_share":1.77,"price_display":"1.77","price_state":"stated","total_value":5310.0,"total_display":"5,310.00","total_whole":"5,310","shares_owned_after":22449.0,"shares_owned_after_display":"22,449","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-21","filed_date":"2025-05-23","scope":"insider"},{"id":2831504,"accession":"0001683168-24-004126","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001683168-24-004126","line_url":"/filing/0001683168-24-004126#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":0.74,"price_display":"0.74","price_state":"stated","total_value":740.0,"total_display":"740.00","total_whole":"740","shares_owned_after":20990.0,"shares_owned_after_display":"20,990","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-07","filed_date":"2024-06-11","scope":"insider"},{"id":2971566,"accession":"0001683168-24-004089","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001683168-24-004089","line_url":"/filing/0001683168-24-004089#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":0.75,"price_display":"0.75","price_state":"stated","total_value":750.0,"total_display":"750.00","total_whole":"750","shares_owned_after":19990.0,"shares_owned_after_display":"19,990","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-06","filed_date":"2024-06-10","scope":"insider"},{"id":2971531,"accession":"0001683168-24-001216","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001683168-24-001216","line_url":"/filing/0001683168-24-001216#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500.0,"shares_display":"2,500","price_per_share":0.91,"price_display":"0.91","price_state":"stated","total_value":2275.0,"total_display":"2,275.00","total_whole":"2,275","shares_owned_after":18990.0,"shares_owned_after_display":"18,990","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-26","filed_date":"2024-02-27","scope":"insider"},{"id":8372581,"accession":"0001209191-23-041254","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-041254","line_url":"/filing/0001209191-23-041254#line-2","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":2.84,"price_display":"2.84","price_state":"stated","total_value":2840.0,"total_display":"2,840.00","total_whole":"2,840","shares_owned_after":19211.0,"shares_owned_after_display":"19,211","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-07-01","filed_date":"2023-07-05","scope":"insider"},{"id":8372576,"accession":"0001209191-23-041254","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-041254","line_url":"/filing/0001209191-23-041254#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":2.88,"price_display":"2.88","price_state":"stated","total_value":2880.0,"total_display":"2,880.00","total_whole":"2,880","shares_owned_after":18211.0,"shares_owned_after_display":"18,211","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-30","filed_date":"2023-07-05","scope":"insider"},{"id":6854865,"accession":"0001209191-22-061471","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-061471","line_url":"/filing/0001209191-22-061471#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Interim Executive Chairman)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Interim Executive Chairman","security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":0.39,"price_display":"0.39","price_state":"stated","total_value":780.0,"total_display":"780.00","total_whole":"780","shares_owned_after":74541.0,"shares_owned_after_display":"74,541","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-14","filed_date":"2022-12-15","scope":"insider"},{"id":6754652,"accession":"0001209191-22-060358","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-060358","line_url":"/filing/0001209191-22-060358#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Interim Executive Chairman)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Interim Executive Chairman","security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":0.39,"price_display":"0.39","price_state":"stated","total_value":780.0,"total_display":"780.00","total_whole":"780","shares_owned_after":72541.0,"shares_owned_after_display":"72,541","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-07","filed_date":"2022-12-08","scope":"insider"},{"id":6400032,"accession":"0001209191-22-060009","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-060009","line_url":"/filing/0001209191-22-060009#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Interim Executive Chairman)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Interim Executive Chairman","security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":0.43,"price_display":"0.43","price_state":"stated","total_value":860.0,"total_display":"860.00","total_whole":"860","shares_owned_after":70541.0,"shares_owned_after_display":"70,541","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-05","filed_date":"2022-12-06","scope":"insider"},{"id":6854606,"accession":"0001209191-22-058942","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-058942","line_url":"/filing/0001209191-22-058942#line-2","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Interim Executive Chairman)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Interim Executive Chairman","security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":215.0,"shares_display":"215","price_per_share":0.4,"price_display":"0.40","price_state":"stated","total_value":86.0,"total_display":"86.00","total_whole":"86","shares_owned_after":68541.0,"shares_owned_after_display":"68,541","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-29","filed_date":"2022-11-29","scope":"insider"},{"id":6854601,"accession":"0001209191-22-058942","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-058942","line_url":"/filing/0001209191-22-058942#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Interim Executive Chairman)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Interim Executive Chairman","security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500.0,"shares_display":"2,500","price_per_share":0.42,"price_display":"0.42","price_state":"stated","total_value":1050.0,"total_display":"1,050.00","total_whole":"1,050","shares_owned_after":68326.0,"shares_owned_after_display":"68,326","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-25","filed_date":"2022-11-29","scope":"insider"},{"id":6788124,"accession":"0001209191-22-057333","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-057333","line_url":"/filing/0001209191-22-057333#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"Phio Pharmaceuticals Corp.","issuer_ticker":"PHIO","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director, Officer (Interim Executive Chairman)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Interim Executive Chairman","security_title":"Series D Preferred Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1.0,"shares_display":"1","price_per_share":1750.0,"price_display":"1,750.00","price_state":"stated","total_value":1750.0,"total_display":"1,750.00","total_whole":"1,750","shares_owned_after":1.0,"shares_owned_after_display":"1","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-16","filed_date":"2022-11-16","scope":"insider"},{"id":8919743,"accession":"0001209191-15-006039","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-006039","line_url":"/filing/0001209191-15-006039","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"RXi Pharmaceuticals Corp","issuer_ticker":"RXII","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":1.196294,"price_display":"1.20","price_state":"stated","total_value":5981.47,"total_display":"5,981.47","total_whole":"5,981","shares_owned_after":4647.0,"shares_owned_after_display":"4,647","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-01-22","filed_date":"2015-01-23","scope":"insider","n_lines":2},{"id":5417034,"accession":"0001181431-13-046524","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-13-046524","line_url":"/filing/0001181431-13-046524#line-1","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"RXi Pharmaceuticals Corp","issuer_ticker":"RXII","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":3.9,"price_display":"3.90","price_state":"stated","total_value":1950.0,"total_display":"1,950.00","total_whole":"1,950","shares_owned_after":1500.0,"shares_owned_after_display":"1,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-08-26","filed_date":"2013-08-27","scope":"insider"},{"id":5416915,"accession":"0001181431-13-042815","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001181431-13-042815","line_url":"/filing/0001181431-13-042815","is_derivative":false,"issuer_cik":"0001304395","issuer_name":"RXi Pharmaceuticals Corp","issuer_ticker":"RXII","issuer_name_source":null,"issuer_url":"/issuer/0001304395","owner_cik":"0001304395","owner_name":"Bitterman Robert J","owner_display_name":"Bitterman Robert J","owner_url":"/insider/0001304395","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common stock, par value $0.0001","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":4.083,"price_display":"4.08","price_state":"stated","total_value":4083.0,"total_display":"4,083.00","total_whole":"4,083","shares_owned_after":500.0,"shares_owned_after_display":"500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-08-05","filed_date":"2013-08-05","scope":"insider","n_lines":5}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":29,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":29,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":29},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001533040","name":"Phio Pharmaceuticals Corp.","url":"/issuer/0001533040","role":"Director, Officer (Chairman, Pres. & CEO)","n_filings":21,"first_seen":"2013-08-05","last_seen":"2026-08-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001304395","retrieved_at":"2026-08-26T20:44:59+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}